The Wistar Institute’s Post

🔬 Week In Review Spotlight! 🔬 This week, the most read paper in The(Sugar)Science's Week In Review (WiR) is "Identification of Immune Gene Signature Associated with T Cells and Natural Killer Cells in Type 1 Diabetes" by Na Wang, Guofeng Wang, Xiuli Feng, and Teng Yang. This groundbreaking research uncovers key immune gene signatures linked to T cells and natural killer cells in T1D, offering valuable insights for the diabetes research community. Don't miss out on the latest research updates! Sign up for our Week In Review (WiR) to stay informed about the top papers, clinical trials, and more in T1D research. 📄 Read the Paper https://lnkd.in/d3vjczee ✉️ Sign Up for WiR https://lnkd.in/gzF897td #T1D #DiabetesResearch #ImmuneGeneSignature #TCells #NaturalKillerCells #WiR #TheSugarScience #ScientificResearch

"Ready or not, here I come" sang the Delfonics in 1968 (and the Fugees much later in 2010) and it seems that the same could be said for genomic newborn screening as it seems increasingly a question of when rather than if. In this new publication, Betzler et al take a look at the list of proposed gene lists that different genomic screening pilots have chosen to see what has been chosen and why. Could a consensus on gene targets ever be reached? Comparative analysis of gene and disease selection in genomic newborn screening studies Isabel Betzler, Maja Hempel, Ulrike Mütze, Stefan Kölker, Eva Winkler, Nicola Dikow, Sven Garbade, Christian Schaaf, Dr. med. Heiko Brennenstuhl, MD, MBA https://lnkd.in/eDFb94HR #newbornscreening #WGS #WES

Follicular helper T cells (#TFH cells) assist #Bcells in producing antibodies. However, too many TFH cells over-activate B cells, which leads to autoimmune diseases like #lupus (#SLE). Not much is known about the molecular mechanisms of TFH differentiation and function. This research paper attached below identifies ETV5 transcription factor and osteoponin secretion (that is controlled by ETV5 via SPP1 gene) as key factors of TFH differentiation . Very interesting and novel research - the article is attached in the comments.

Ever wondered how we can use the power of the epigenome to treat complex diseases? In the latest episode of Life Sciences 360, I had a valuable conversation with Brian Cosgrove, Principal Scientist at Tune Therapeutics. Here's what we covered: 🔹 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀: How Tune Therapeutics is using epigenetic tuning to develop groundbreaking treatments. 🔹 𝗧𝗲𝗺𝗽𝗼 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺: Get to know the new Tempo platform and its potential to precisely control gene expression. 🔹 𝗛𝗲𝗽𝗮𝘁𝗶𝘁𝗶𝘀 𝗕 𝗕𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵: Exciting developments in treating hepatitis B with the Tune 401 program. 👀 This episode JUST released, Go Watch Now: https://lnkd.in/eP8ZxGrV

Timothy J. Taxter, M.D. presenting now our new Endometrial prognosticator. Here we show how we divide NSMP into a new high risk subtype that is characterized by low levels of expression of ESR1 and high genomic fragmentation. Session PO.CL01.10 - Predictive Biomarkers 5 , Section 43 6416 / 28 - Early stage endometrioid endometrial cancer recurrence risk stratification using a machine learning RNA-seq gene expression signature                          #Tempus #AACR24

WEBINAR ALERT! Join us for an insightful session with Jessica Koepke and João Cotovio to discover the applications of Ncyte® aCardiomyocytes in toxicity, and gene modulation assays. In this webinar, you will learn about the quality control and characterization of Ncyte® aCardiomyocytes, as well as examples of their applications in drug discovery and the advantages of using chamber-specific cardiomyocytes. Don't miss out on this opportunity to learn from experts in the field! Choose the session that best fits your time zone: For our European audience: Wednesday, August 28th at 3:30 PM CEST Register here: https://lnkd.in/dVeqGTNX For our US audience: Wednesday, August 28th at 1:00 PM ET Register here: https://lnkd.in/d4c72SJy Secure your spot and gain valuable insights! #Webinar #Cardiomyocytes #cardiacdisease #DrugDiscovery #CellBasedAssay #Ncardia

Dear all! Join Proteintech´s next Webinar: "Visualization of m6A residues in individual mRNAs". When: May 30th, 2024 | 2pm US CT | 2pm BST | 3pm CEST Event info: Join Charles Sheehan, a PhD candidate from Duke University Medical Center, as he presents groundbreaking research on DART-FISH,offering unparalleled insights into mRNA methylation dynamics. N6-methyladenosine (m6A) is an abundant RNA base modification and is critical for regulating gene expression. While traditional sequencing-based approaches have enabled invaluable insights into m6A function, methods for visualizing m6A-modified mRNAs in cells are currently lacking. In this webinar, Charles Sheehan will share his work on a novel method that enables the simultaneous visualization of methylated and unmethylated mRNA molecules in cells. That has the potential for unprecedented insights into the regulation of methylated transcripts in health and disease. The workshop will include: ·        Detailed Q&A with the speaker ·        Free product sample ·        A certificate of attendance and a link to watch the webinar will be available to attendees post-event. Register here: https://lnkd.in/dmuPX9n4 See you there!

🔬 Exciting News! Just completed a gene expression analysis project on cancer datasets sourced from the GDC portal and GTEx. 🧬 Check out the insights and findings on my GitHub repository! 👉 https://lnkd.in/gw6NfW2V #Bioinformatics #Genomics #DataAnalysis #CancerResearch #GitHub #DataScience #computationalbiology

Just came across an interesting article that highlights some exciting new developments in the industry. It's always fascinating to see innovative approaches and fresh perspectives shaping our field. Highly recommend giving it a read! #Innovation #IndustryNews #ExcitingDevelopments #ProfessionalGrowth #crohnsandcolitiscanada

I am incredibly proud to share the development of GeneArchitect, a cutting-edge tool designed to enhance CRISPR research. GeneArchitect enables researchers to precisely design, simulate, and optimize gene editing experiments, bringing us closer to groundbreaking treatments for various genetic diseases. Understanding the importance of CRISPR technology in the research and cure of diseases such as cancer, cystic fibrosis, and sickle cell anemia is crucial. This tool not only aids in the scientific study of gene editing but also paves the way for personalized therapies that could transform the lives of countless individuals. Check out the presentation below to see how GeneArchitect can assist in the study and development of CRISPR-based therapies and our exciting next steps. GeneArchitect: "Modeling the Future" #CRISPR #GeneEditing #Biotechnology #HealthcareInnovation #GeneArchitect #Biohacking